-+ 0.00%
-+ 0.00%
-+ 0.00%

Tango Therapeutics reports 82% response rate for vopimetostat combination in pancreatic cancer trial

PUBT·10/23/2026 10:34:04
Tango Therapeutics reports 82% response rate for vopimetostat combination in pancreatic cancer trial
  • Tango Therapeutics reported tumor shrinkage and durable disease control with vopimetostat combined with daraxonrasib in previously treated pancreatic cancer.
  • The Phase 1/2 results are being presented at the ESMO Congress in Madrid, Oct. 23-27, 2026.
  • The lower-dose combination was generally well tolerated; the higher-dose regimen was not well tolerated.
  • A registrational Phase 3 trial comparing the combination against chemotherapy in previously untreated, MTAP-deleted pancreatic cancer is planned for first-half 2027.
  • Discussions with regulators will explore potential approval of the combination for second-line pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230630PRIMZONEFULLFEED9851825) on October 23, 2026, and is solely responsible for the information contained therein.